English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 25174373      Online Users : 431
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32515

    標題: Statin use and Vital Organ Failure in Patients With Asthma-Chronic Obstructive Pulmonary Disease Overlap: A Time-Dependent Population-Based Study
    作者: Yeh, Jun-Jun(葉俊濬)
    Syue, Shih-Huei
    Lin, Cheng-Li
    Hsu, Chung Y.
    Shae, Zonyin
    Kao, Chia-Hung
    貢獻者: Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Famiy Med
    Chia Nan Univ Pharm & Sci, Dept Childhood Educ & Nursery
    China Med Univ, Coll Med
    Mei Ho Univ, Dept Nursing
    China Med Univ Hosp, Management Off Hlth Data
    China Med Univ, Coll Med, Grad Inst Biomed Sci
    China Med Univ, Coll Med, Sch Med
    Asia Univ, Dept Comp Sci & Informat Engn
    China Med Univ Hosp, Dept Nucl Med
    Asia Univ, Dept Bioinformat & Med Engn
    關鍵字: asthma-chronic obstructive pulmonary disease overlap (ACO)
    hepatic failure
    renal failure
    heart failure
    respiratory failure
    日期: 2019-08
    上傳時間: 2020-07-29 13:48:07 (UTC+8)
    摘要: Objective: The effects of statins on the risk of hepatic, renal, respiratory, and heart failure among patients with asthma-chronic obstructive pulmonary disease overlap (ACO) have not been reported. Design: Time-dependent population-based study. Setting: Patient data from 2000 to 2010 were retrieved from the Taiwan National Health Insurance Research Database. Patients: We divided patients with ACO into cohorts of statin use (N = 1,211) and nonuse (N = 7,443). Measurements and Main Results: The cumulative incidence rates of hepatic, renal, respiratory, and heart failure were analyzed through Cox proportional regression analysis with time-dependent variables. After adjustment for multiple confounding factors, including age, sex, comorbidities, and medications [statins, inhaled corticosteroid (ICS), or oral steroid (OS)], the adjusted hazard ratios (aHRs) [95% confidence intervals (CIs)] for hepatic, renal, respiratory, and heart failure were 0.50 (0.40-0.64), 0.49 (0.38-0.64), 0.61 (0.27-2.21), and 0.47 (0.37-0.60), respectively. The aHRs (95% Cls) for statin use with [ICS, OS] for hepatic, renal, and heart failure were [0.36 (0.20-0.66), 0.52 (0.39-0.70)]; [0.82 (0.51-1.34), 0.46 (0.33-0.63)]; and [0.66 (0.40-1.07), 0.48 (0.37-0.64)], respectively. Conclusions: The ACO cohort with statin use exhibited lower risk of hepatic, renal, and heart failure than any other cohort, regardless of age, sex, comorbidities, or ICS or OS use. Regarding the combined use of statins and ICS, the risks of hepatic failure were lower. For the combined use of statins and OS, hepatic, renal, and heart failure were less frequent.
    關聯: Frontiers in Pharmacology, v.10, 889
    Appears in Collections:[嬰幼兒保育系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.3389-fphar.2019.00889.pdf1031KbAdobe PDF332View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback